Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Dow

Showing results (141-150 of 164) with videos related to

Pageof 17
Sort By:
Skeletal Muscle|March 20, 2015
NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophyJoe N Kornegay, Jennifer M Peterson, Daniel J Bogan, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonistsRobert L Dow, Ernest S Paight, Steven R Schneider, et al.
ACS Chemical Biology|October 1, 2015
MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1Adam G Schwaid, Chunyan Su, Paula Loos, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted AgentsRobert L Dow, Philip A Carpino, Denise Gautreau, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Journal of Medicinal Chemistry|December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonistDavid A Griffith, John R Hadcock, Shawn C Black, et al.
Epidemiology and Infection|February 25, 1999
An outbreak of viral gastroenteritis associated with consumption of sandwiches: implications for the control of transmission by food handlersU D Parashar, L Dow, R L Fankhauser, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
Journal of Medicinal Chemistry|April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesityRobert L Dow, Philip A Carpino, John R Hadcock, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Pageof 17

Showing results (141-150 of 164) with videos related to

Sort By:
Pageof 17
Skeletal Muscle|March 20, 2015
NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophyJoe N Kornegay, Jennifer M Peterson, Daniel J Bogan, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2004
Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonistsRobert L Dow, Ernest S Paight, Steven R Schneider, et al.
ACS Chemical Biology|October 1, 2015
MAP4K4 Is a Threonine Kinase That Phosphorylates FARP1Adam G Schwaid, Chunyan Su, Paula Loos, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted AgentsRobert L Dow, Philip A Carpino, Denise Gautreau, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2011
Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine coreRobert L Dow, Melissa Andrews, Gary E Aspnes, et al.
Journal of Medicinal Chemistry|December 24, 2008
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonistDavid A Griffith, John R Hadcock, Shawn C Black, et al.
Epidemiology and Infection|February 25, 1999
An outbreak of viral gastroenteritis associated with consumption of sandwiches: implications for the control of transmission by food handlersU D Parashar, L Dow, R L Fankhauser, et al.
Biochemical and Biophysical Research Communications|March 10, 2010
In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesityJohn R Hadcock, David A Griffith, Phillip A Iredale, et al.
Journal of Medicinal Chemistry|April 9, 2009
Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesityRobert L Dow, Philip A Carpino, John R Hadcock, et al.
Bioorganic & Medicinal Chemistry|July 23, 2013
Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitorRobert L Dow, Melissa P Andrews, Jian-Cheng Li, et al.
Pageof 17